



## ASX Announcement

### 2010 Annual General Meeting – Outcome of Resolutions

**Sydney Australia. Monday 15 November 2010** – In accordance with Listing Rule 3.13 the Company advises the outcomes in respect of resolutions put to the annual general meeting of the Company held at noon on 15 November 2010.

#### **Resolution 2 Remuneration report**

“That the Company’s remuneration report for the year ended 30 June 2010 be adopted.”

Total number of proxy votes in respect of the resolution:

In favour of the resolution	320,261,202
Against the resolution	872,750
Abstain from the resolution	136,065

Resolution approved by poll.

#### **Resolution 3(a) Re-election of retiring director**

“That Mr Nicholas Callinan being a director who retires by rotation in accordance with the Company’s bylaws and being eligible, offers himself for re-election, is re-elected as a director of the Company.”

Total number of proxy votes in respect of the resolution:

In favour of the resolution	321,031,952
Against the resolution	146,000
Abstain from the resolution	92,065

Resolution approved by poll.

#### **Resolution 3(b) Re-election of retiring director**

“That Mr Donal O’Dwyer being a director who retires by rotation in accordance with the Company’s bylaws and being eligible, offers himself for re-election, is re-elected as a director of the Company.”

Total number of proxy votes in respect of the resolution:

In favour of the resolution	319,406,952
Against the resolution	146,000
Abstain from the resolution	1,717,065

Resolution approved by poll.

### **About Sunshine Heart**

Sunshine Heart (ASX: SHC), a global medical device company focused on innovative technologies for the treatment of moderate heart failure, is commercializing the C-Pulse® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. The C-Pulse System is designed to relieve the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart's pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20-patient U.S. feasibility clinical trial with the C-Pulse System and the study has achieved eighty percent enrolment as of October 2010. Sunshine Heart, Inc. is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004. For more information, please visit [www.sunshineheart.com](http://www.sunshineheart.com).

For further information, please visit [www.sunshineheart.com](http://www.sunshineheart.com) or contact:

Dave Rosa

Chief Executive Officer

+1 952 345 4200

[dave.rosa@sunshineheart.com](mailto:dave.rosa@sunshineheart.com)

Rowena Hubble

Company Secretary

+61 2 8424 7700

[rowena.hubble@sunshineheart.com](mailto:rowena.hubble@sunshineheart.com)

Andrew Geddes

CoActive Health Communications

+ 61 2 9555 4453 or 0408 677 734

[ageddes@coactivepr.com](mailto:ageddes@coactivepr.com)

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Securities Exchange.

The shares of Sunshine Heart have not been registered under the Securities Act of 1933 (**US Securities Act**) and may not be offered, sold or delivered in the United States, or to, or for the account or benefit of, any US Person, as such term is defined in Regulation S of the US Securities Act. In addition, hedging transactions with regard to the shares may not be conducted unless in accordance with the US Securities Act.